Calidi Biotherapeutics (Calidi Biotherapeutics) Change In Receivables : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Calidi Biotherapeutics Change In Receivables?

Calidi Biotherapeutics's change in receivables for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Calidi Biotherapeutics's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Calidi Biotherapeutics's change in receivables for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Calidi Biotherapeutics's Accounts Receivable stayed the same from Dec. 2022 to Dec. 2023 .

Calidi Biotherapeutics's Accounts Receivable for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Calidi Biotherapeutics's liquidation value for the three months ended in Mar. 2024 was $-20.84 Mil.

Calidi Biotherapeutics Change In Receivables Historical Data

The historical data trend for Calidi Biotherapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calidi Biotherapeutics Change In Receivables Chart

Calidi Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Calidi Biotherapeutics Quarterly Data
	Dec20	Sep21	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial					-	-	-	-	-

Calidi Biotherapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Calidi Biotherapeutics (AMEX:CLDI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Calidi Biotherapeutics's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Calidi Biotherapeutics's accounts receivable are only considered to be worth 75% of book value:

Calidi Biotherapeutics's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1.143	-	21.978	+	0.75 * 0	+	0.5 * 0
=	-20.84

Calidi Biotherapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Calidi Biotherapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Calidi Biotherapeutics (Calidi Biotherapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calidi Biotherapeutics Inc (AMEX:CLDI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

11011 North Torrey Pines Road, Suite 200, La Jolla, CA, USA, 92037

Website

https://www.calidibio.com

Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.

Calidi Biotherapeutics (Calidi Biotherapeutics) Headlines

From GuruFocus

Calidi Biotherapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Mone(TM) Show on Bloomberg TV

By ACCESSWIRE • 05-17-2024